Compare UTMD & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTMD | RPID |
|---|---|---|
| Founded | 1978 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.4M | 204.3M |
| IPO Year | N/A | 2021 |
| Metric | UTMD | RPID |
|---|---|---|
| Price | $61.04 | $4.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 12.3K | ★ 311.8K |
| Earning Date | 01-30-2026 | 02-27-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.54 | N/A |
| Revenue | ★ $38,633,000.00 | $30,523,000.00 |
| Revenue This Year | N/A | $19.36 |
| Revenue Next Year | N/A | $21.48 |
| P/E Ratio | $17.33 | ★ N/A |
| Revenue Growth | N/A | ★ 16.63 |
| 52 Week Low | $51.26 | $1.10 |
| 52 Week High | $65.56 | $4.88 |
| Indicator | UTMD | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 59.15 |
| Support Level | $58.25 | $2.92 |
| Resistance Level | $64.02 | $4.88 |
| Average True Range (ATR) | 1.40 | 0.38 |
| MACD | 0.34 | 0.15 |
| Stochastic Oscillator | 63.90 | 61.22 |
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.